Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Oct 14, 2020 6:05pm
196 Views
Post# 31718367

RE:RE:RE:RE:RE:RE:RE:Don’t get shaken out!

RE:RE:RE:RE:RE:RE:RE:Don’t get shaken out!
JHendrix wrote: Closer to $2 makes sense.  They need to ramp SP to $4US for NAS. So, are they going to drive it with news in coming months to be on NAS before or close to Aristotle. Or do they launch Aristotle and let SP grow organically to $4US to get on NAS.  Maybe Locust Analytics has  formulated the approach.



I think the big factor here is the Clarus call that we might name an affiliate soon for Aristotle with a medical facility - if that happens to be a large credible one then I see a huge reaction to such an NR and the sp hitting highs higher than discussed here. That would pretty much guarantee acceptance of the medical tech and pave the way to accessing the hundreds of billions market worldwide.
<< Previous
Bullboard Posts
Next >>